Zuranolone (Zurzuvae): Fourteen Days of Tablets for Postpartum Depression — and Why It Is Not a Pill for Depression in General
Ukraine, Dnepr, st. 25 Sicheslavskaya Brigade (Rybinskaya St.), 119 ‑ 120
Ukraine, Dnepr, st. 25 Sicheslavskaya Brigade (Rybinskaya St.), 119 ‑ 120

Zuranolone (Zurzuvae): Fourteen Days of Tablets for Postpartum Depression — and Why It Is Not a Pill for Depression in General

A guide to zuranolone (Zurzuvae), the first tablet approved by the FDA specifically for postpartum depression: how it replaces the neurosteroid that collapses after birth, the SKYLARK and ROBIN numbers, a fourteen-day course and who should see a doctor first.

Zuranolone (Zurzuvae): Fourteen Days of Tablets for Postpartum Depression — and Why It Is Not a Pill for Depression in General
Through pregnancy the level of allopregnanolone — the calming metabolite of progesterone — rises over months. After birth it collapses within hours, and receptors accustomed to the high level cannot readjust that fast. Zuranolone restores exactly that missing piece, which is why it works in days rather than weeks: the course is 14 days, and separation from placebo is visible from the third day.

Key points

Zuranolone (Zurzuvae) is a tablet for postpartum depression that replaces the neurosteroid that collapsed after birth; the course is 14 days.

SituationHow it helpsWhat human studies showed
Postpartum depressionreplaces the allopregnanolone that collapsed after birthSKYLARK (Am J Psychiatry, 2023), 196 patients: by day 15 the HAM-D score had fallen by 15.6 points versus 11.6 on placebo (difference −4.0; 95% CI −6.3 to −1.7) [1]; ROBIN (JAMA Psychiatry, 2021), 153 patients: by day 15, −17.8 versus −13.6 points (difference −4.2; p=0.003) [2]
Fast effectdays rather than the weeks antidepressants needseparation from placebo as early as day 3 [1, 2]
Response and remissionmore often than on placebothe odds of response rose roughly 2.6-fold and of remission about 2.5-fold [2]
After the course endsa course of just 14 daysseparation held at days 28 and 45 [1] and from day 3 through day 45 [2]
Treatment at homea tablet at home instead of a brexanolone infusion of roughly 60 hours in hospital—

How it helps

What collapses after birth

Progesterone has a metabolite: allopregnanolone. It is a neurosteroid — a substance produced partly in the brain itself and acting directly on how the brain works. Its job is to strengthen GABA, the main inhibitory system of the nervous system. In plain terms, it turns excitation down.

Through pregnancy its level rises many-fold, and the brain gradually adjusts to that high background: receptor sensitivity shifts and the system settles into a new equilibrium.

After birth the level falls within hours. In most women the receptors readjust. In some they do not, and the inhibitory system is left destabilised. That is the biological trigger of postpartum depression — on top of sleeplessness, workload and everything else a newborn brings.

Why it works in days

Standard antidepressants work through the serotonin system. They do not replace a deficit directly; they change the conditions the brain then adapts to over weeks. Hence the familiar two to four weeks before an effect appears.

For a woman with a newborn that is a very long time. Depression in this period does not strike her alone: bonding with the child suffers, and so does the whole family.

Zuranolone is built on a different logic: return the missing piece rather than retune the system. It reproduces the action of allopregnanolone, strengthening GABA receptors — including the extrasynaptic ones that set overall inhibitory tone.

Antidepressants (SSRIs)Zuranolone
TargetSerotonin systemGABA receptors via a neurosteroid
Time to effectWeeksDays (separation from day 3)
Duration of dosingMonths14 days
Indication in postpartum depressionYes (general)Yes (specific)

How to take it

ParameterDetail
FormulationCapsules
WhenIn the evening, with a fatty meal
Course14 days, then stop
DrivingProhibited for at least 12 hours after a dose
StatusControlled substance
Follow-upClinical assessment during the course

Evening dosing is not a convention but a way of placing the peak of sedation inside the night.

Who should see a doctor first

Side effects. The most frequent adverse events were somnolence, dizziness and sedation. No loss of consciousness, withdrawal symptoms or increase in suicidal ideation was observed in SKYLARK [1].

What to know beforehand

▸ Sedation. Somnolence and dizziness are the most frequent effects. The boxed warning says it plainly: the ability to drive is impaired, and the woman may not realise how much.
▸ Care of the baby. Across the two weeks someone must be available to take night care. This is agreed before starting, not improvised along the way.
▸ Breastfeeding. Data on passage into milk exist but are limited; the decision is individual.
▸ Controlled substance. Hence the specific prescribing and dispensing arrangements.

Who it is not for

▸ Women with depression outside the postpartum period, under the current indication.
▸ Anyone who will be alone with the baby for two weeks: sedation makes that unsafe.
▸ Anyone counting on driving as usual.
▸ As a substitute for monitoring: severe postpartum depression with suicidal thoughts needs immediate help, not a wait for a tablet to work.

Bottom line

▸ A physiological mechanism: the drug reproduces the allopregnanolone that collapsed after birth and, through GABA, gives the inhibitory system its footing back.
▸ Speed: separation from placebo is visible from the third day, not after a month.
▸ A 14-day course, not months of dosing; in the trials the effect held to day 45.
▸ The indication is postpartum depression; during the course, no driving and a helper close by.

The condition can be discussed at a consultation; the drug can be ordered here.

References

1. Deligiannidis KM, et al. Zuranolone for the Treatment of Postpartum Depression. Am J Psychiatry. 2023;180(9):668–675. PMID 37491938

2. Deligiannidis KM, et al. Effect of Zuranolone vs Placebo in Postpartum Depression: A Randomized Clinical Trial. JAMA Psychiatry. 2021;78(9):951–959. PMID 34190962

3. Deligiannidis KM, et al. Zuranolone Concentrations in the Breast Milk of Healthy, Lactating Individuals: Results From a Phase 1 Open-Label Study. J Clin Psychopharmacol. 2024;44(4):337–344. PMID 38739007

4. ZURZUVAE (zuranolone) — US Prescribing Information, Sage Therapeutics and Biogen.

Source: Zuranolone (Zurzuvae): Fourteen Days of Tablets for Postpartum Depression — and Why It Is Not a Pill for Depression in General — universum.earth. Dr. Pereligyn.

Come back
Request a call back